Ringside’s phase 3 findings reveal the potential varegacestat has to deliver “best-in-class results in a convenient, ...

Argenx discontinues its Phase 3 UplighTED trial in thyroid eye disease after an interim futility review, while analysts maintain confidence in Vyvgart's broader growth.

Kyverna Therapeutics looks all the more likely to win the first FDA approval for a CAR-T therapy in an autoimmune disease ...

C3.ai delivered $145.4 million in total revenue during the first half of its fiscal year 2026 (ended Oct. 31), which was down ...

Explore adaptive AI SEO tools of 2026. Intelligent, data-driven systems that learn and refine search performance automatically.

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

Crouched between mountains of discarded plastic, Lanh strips the labels off bottles of Coke, Evian and local Vietnamese tea drinks so they can be melted into tiny pellets for reuse.

If 2024 was the year of proof-of-concept and 2025 was the year of early adoption and scale, 2026 is shaping up to be something different — a year defined by normalization. AI in healthcare won't fade ...

Your Moneyist column has been so helpful in the past. I now have a question: My son and daughter-in-law want to purchase their first home in the Mid-Atlantic region. They plan to spend $600,000. But ...

A Thai government agency has kicked off a campaign calling for a transition to a plant-rich food system, citing better health ...

Micron Technology's fair value estimate has been lifted sharply to about $249.31 per share, while the discount rate has ...